Cortazar, P., L. Zhang, M. Untch, K. Mehta, J. Costantino, N. Wolmark, H. Bonnefoi, D. Cameron, L. Gianni, P. Valagussa, J. Zujewski, R. Justice, S. Loibl, L. Wickerham, J. Bogaerts, J. Baselga, C. Perou, G. Blumenthal, J. Blohmer, E. Mamounas, J. Bergh, V. Semiglazov, T. Prowell, H. Eidtmann, S. Paik, M. Piccart, R. Sridhara, P. Fasching, S. Swain, L. Slaets, S. Tang, B. Gerber, C. Geyer, R. Pazdur, N. Ditsch, P. Rastogi, W. Eiermann, and G. von Mincwitz. 2012. Meta-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNEOBC). Paper presented at San Antonio Breast Cancer Symposium, San Antonio, TX, December 5.

Dodd, L. E., E. L. Korn, B. Freidlin, C. C. Jaffe, L. V. Rubinstein, J. Dancey, and M. M. Mooney. 2008. Blinded independent central review of progression-free survival in phase III clinical trials: Important design element or unnecessary expense? Journal of Clinical Oncology 26(22):3791-3796.

Eichler, H. G., K. Oye, L. G. Baird, E. Abadie, J. Brown, C. L. Drum, J. Ferguson, S. Garner, P. Honig, M. Hukkelhoven, J. C. Lim, R. Lim, M. M. Lumpkin, G. Neil, B. O’Rourke, E. Pezalla, D. Shoda, V. Seyfert-Margolis, E. V. Sigal, J. Sobotka, D. Tan, T. F. Unger, and G. Hirsch. 2012. Adaptive licensing: Taking the next step in the evolution of drug approval. Clinical Pharmacology and Therapeutics 91(3):426-437.

EMA (European Medicines Agency). 2010. Questions and answers on the review of avastin (bevacizumab) in the treatment of metastatic breast cancer. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2010/12/WC500099939.pdf (accessed May 16, 2013).

FDA (Food and Drug Administration). 2006. Information sheet guidance for IRBs, clinical investigators, and sponsors: Significant risk and nonsignificant risk medical device studies. http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126418.pdf (accessed May 9, 2013).

———. 2012a. Draft guidance for industry and FDA staff. Medical devices: The pre-submission program and meetings with FDA staff. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm310375.htm (accessed May 9, 2013).

———. 2012b. FDA briefing document. Oncologic drugs advisory committee meeting. July 24, 2012. Evaluation of radiologic review of progression-free survival in non-hematologic malignancies. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM311141.pdf (accessed May 9, 2013).

———. 2012c. Guidance for industry on determining the extent of safety data collection needed in late stage premarket and postapproval clinical investigations. https://s3.amazonaws.com/public-inspection.federalregister.gov/2012-03096.pdf (accessed May 9, 2013).

———. 2012d. Guidance for IRBs, clinical investigators and sponsors: IRB responsibilities for reviewing the qualifications of investigators, adequacy of research sites, and the determination of whether an IND/IDE is needed. http://www.fda.gov/RegulatoryInformation/Guidances/ucm366335.htm (accessed May 9, 2013).

———. 2012e. Kalydeco (ivacaftor) information. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm323671.htm (accessed May 9, 2013).

Freidlin, B., L. M. McShane, and E. L. Korn. 2010. Randomized clinical trials with biomarkers: Design issues. Journal of the National Cancer Institute 102(3):152-160.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement